17,186 results match your criteria Breast Cancer and HER2


Squalamine blocks tumor-associated angiogenesis and growth of human breast cancer cells with or without HER-2/neu overexpression.

Cancer Lett 2019 Feb 13. Epub 2019 Feb 13.

Department of Medicine, Division of Hematology-Oncology, UCLA David Geffen School of Medicine, Los Angeles, CA, 90095; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, 90095. Electronic address:

Angiogenesis is critical for breast cancer progression. Overexpression of HER-2/neu receptors occur in 25-30% of breast cancers, and treatment with trastuzumab inhibits HER-2-overexpressing tumor growth. Notably, HER-2-mediated signaling enhances vascular endothelial growth factor (VEGF) secretion to increase tumor-associated angiogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2019.02.009DOI Listing
February 2019

Esophageal metastasis of breast cancer during endocrine therapy for pleural dissemination 21 years after breast surgery: a case report.

Surg Case Rep 2019 Feb 15;5(1):22. Epub 2019 Feb 15.

Department of Gastroenterological Surgery, Yokohama City University School of Medicine, Fukuura 3-9, Kanazawa, Yokohama, Kanagawa, 236-0004, Japan.

Background: The esophageal metastasis of breast cancer is rare. Moreover, it is extremely unusual for patients to experience the symptoms of esophageal metastasis during their lifetimes. We present a case of dysphagia caused by esophageal metastasis after a long interval following a primary mastectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40792-019-0585-xDOI Listing
February 2019

Current Treatment Options for Breast Cancer Brain Metastases.

Curr Treat Options Oncol 2019 Feb 15;20(3):19. Epub 2019 Feb 15.

Department of Medicine, Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, 9500 Euclid Ave, S73, Cleveland, OH, 44195, USA.

Opinion Statement: In the past, the standard of care for treatment of BM was whole brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), and surgery. There has been a greater role for medical therapies in the last two decades due to the discovery of driver mutations and corresponding targeted therapies. These innovations have dramatically altered the approach to treating these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0618-5DOI Listing
February 2019

Expression pattern of microRNAs related with response to trastuzumab in breast cancer.

J Cell Physiol 2019 Feb 15. Epub 2019 Feb 15.

Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Background: Although an immense effort has been made to develop a novel biomarker for response to trastuzumab, no reliable biomarkers are available to guide management, expect for HER2. The aim of this study was to examine the relationship between microRNA (miRNA) expression and resistance to trastuzumab.

Methods: Differentially expressed miRNAs between trastuzumab-resistant and trastuzumab-sensitive cell lines were analyzed using microarrays. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.28268DOI Listing
February 2019

Clinical Features, Survival and Prognostic Factors of Glycogen-Rich Clear Cell Carcinoma (GRCC) of the Breast in the U.S. Population.

J Clin Med 2019 Feb 14;8(2). Epub 2019 Feb 14.

Department of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine, Lexington, KY 40536, USA.

The World Health Organization (WHO) defines glycogen-rich clear cell carcinoma (GRCC) of the breast as a carcinoma with glycogen accumulation in more than 90% of its tumor cells. Due to the rarity of this disease, its reported survival and clinical associations have been inconsistent due to reliance on case reports and limited case series. As a result, the prognostic implication of this cancer subtype remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm8020246DOI Listing
February 2019

Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer.

Future Oncol 2019 Feb 15. Epub 2019 Feb 15.

Medical Affairs, Pfizer Japan Inc., Tokyo, Japan.

Biologics have dramatically changed breast cancer treatment, and trastuzumab has been an essential treatment drug for HER2-positive breast cancer. The introduction of trastuzumab biosimilar offers the potential to deliver long-term cost savings plus efficiencies for healthcare systems in Japan. The goal of biosimilar development is to demonstrate comparability to the original biologic with a different development concept from that of the original biologic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0957DOI Listing
February 2019

Stromal expression of CD10 in breast carcinoma and its correlation with clinicopathological parameters.

South Asian J Cancer 2019 Jan-Mar;8(1):18-21

Department of Pathology, Smt. Kashibai Navale Medical College and General Hospital, Pune, Maharashtra, India.

Introduction: Breast cancer is the foremost cause of death in women worldwide with more than one million cases occurring annually.

Aim: This study was conducted to study the stromal CD10 expression in breast carcinomas (BCa) and its correlation with various prognostic factors such as tumor size, histological grade, lymph node status, estrogen receptor (ER), progesterone receptor (PR), HER2neu, and Ki67 status.

Materials And Methods: Sixty cases of BCa diagnosed between 2013 and 2015 were included in the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/sajc.sajc_56_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348787PMC
February 2019

[A Case of Drug-Induced Interstitial Lung Disease Associated with Epirubicin and Cyclophosphamide Therapy before Operation].

Gan To Kagaku Ryoho 2019 Jan;46(1):160-162

Dept. of Surgery, Fukaya Red Cross Hospital.

We report the case of a 60-year-old woman with right breast cancer. Approximately 18 years had passed since the treatment for left breast cancer without recurrence. She became aware of the right breast tumor with mild pain 5 months before she came to the hospital. Read More

View Article

Download full-text PDF

Source
January 2019

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

Lancet Oncol 2019 Feb 11. Epub 2019 Feb 11.

Institut Gustave Roussy, Université Paris Sud, INSERM U981, Villejuif, France.

Background: HER2-positive breast cancers usually contain large amounts of T-cell infiltrate. We hypothesised that trastuzumab resistance in HER2-positive breast cancer could be mediated by immune mechanisms. We assessed the safety and anti-tumour activity of pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, added to trastuzumab in trastuzumab-resistant, advanced HER2-positive breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30812-XDOI Listing
February 2019

Is There a Benefit of HER2-Positive Breast Cancer Subtype Determination in Clinical Practice?

Klin Onkol 2019 ;32(1):25-30

Background: Breast cancer (BC) with increased expression of human epidermal growth factor receptor 2 with tyrosine kinase activity (HER2+) is a clinically and bio-logically heterogeneous dis-ease. In terms of gene expression, there are four major molecular subtypes - Luminal A, Luminal B, HER2-enriched (HER2-E), and Basal-like. The most common subtype is HER2-E (50- 60%). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14735/amko2019DOI Listing
January 2019
1 Read

Discrimination of breast cancer from benign tumours using Raman spectroscopy.

PLoS One 2019 14;14(2):e0212376. Epub 2019 Feb 14.

Qatar Biomedical Research Institute, Doha, Qatar.

Breast cancer is the most common cancer among women worldwide, with an estimated 1.7 million cases and 522,000 deaths in 2012. Breast cancer is diagnosed by histopathological examination of breast biopsy material but this is subjective and relies on morphological changes in the tissue. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0212376PLOS
February 2019

Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response.

PLoS One 2019 14;14(2):e0210891. Epub 2019 Feb 14.

University Hospital Geelong, Geelong, Victoria, Australia.

Background: This study evaluated the feasibility of achieving high response rates in stage II or III breast cancer by tailoring neoadjuvant therapy using clinical and histopathological features and the Oncotype DX Breast Recurrence Score. Genomic determinants of response and resistance were also explored.

Patients And Outcome Measures: Fifty-one patients were enrolled. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0210891PLOS
February 2019

Comparison of breast cancer risk factors among molecular subtypes: A case-only study.

Cancer Med 2019 Feb 14. Epub 2019 Feb 14.

Key Laboratory of Breast Cancer Prevention and Therapy in Ministry of Education, Key Laboratory of Molecular Cancer Epidemiology of Tianjin, Department of Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China.

Epidemiological studies have a clear definition of the risk factors for breast cancer. However, it is unknown whether the distribution of these factors differs among breast cancer subtypes. We conducted a hospital-based case-only study consisting of 8067 breast cancer patients basing on the Tianjin Cohort of Breast Cancer Cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2012DOI Listing
February 2019

Cancer Cell Targeting With Functionalized Quantum Dot-Encoded Polyelectrolyte Microcapsules.

Front Chem 2019 30;7:34. Epub 2019 Jan 30.

Laboratory of Nano-Bioengineering, Moscow Engineering Physics Institute, National Research Nuclear University MEPhI, Moscow, Russia.

Imaging agents and drug carriers are commonly targeted toward cancer cell through functionalization with specific recognition molecules. Quantum dots (QDs) are fluorescent semiconductor nanocrystals whose extraordinary brightness and photostability make them attractive for direct fluorescent labeling of biomolecules or optical encoding of the membranes and cells. Here, we analyse the cytotoxicity of QD-encoded microcapsules, validate an approach to the activation of the microcapsule's surface for further functionalization with monoclonal antibody Trastuzumab, a humanized monoclonal antibody targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2) and already in clinical use for the treatment of HER2 positive breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fchem.2019.00034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363708PMC
January 2019

EYA2 Correlates With Clinico-Pathological Features of Breast Cancer, Promotes Tumor Proliferation, and Predicts Poor Survival.

Front Oncol 2019 29;9:26. Epub 2019 Jan 29.

Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Eyes absent homolog 2 (EYA2), a transcriptional activator, is pivotal for organ development, but aberrant regulation of EYA2 has been reported in multiple human tumors. However, the role of EYA2 in breast cancer is still lack of full understanding. To explore the biological significance of EYA2 in breast cancer, we conducted data analysis on public breast cancer datasets, and performed immunohistochemistry (IHC) analysis, colony-forming unit assays, EdU assay, western blotting, and immunofluorescence (IF). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361843PMC
January 2019

Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy.

Can J Cardiol 2019 Feb 4;35(2):153-159. Epub 2018 Dec 4.

Division of Cardiology, Peter Munk Cardiac Center, Ted Rogers Program in Cardiotoxicity Prevention, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada. Electronic address:

Background: Statins can reduce the risk of anthracycline-induced cardiotoxicity. Whether such cardioprotective effects can be seen in trastuzumab-treated patients has not been explored.

Methods: Consecutive women with HER2+ breast cancer who received trastuzumab with or without anthracyclines were identified retrospectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cjca.2018.11.028DOI Listing
February 2019

New and important changes in breast cancer TNM: incorporation of biologic factors into staging.

Expert Rev Anticancer Ther 2019 Feb 13. Epub 2019 Feb 13.

c Department of Surgery , Cedars-Sinai Medical Center and the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center , Los Angeles , CA .

Introduction: Cancer staging has historically been based solely on the anatomic extent of the tumor (T), spread to lymph nodes (N), and presence of distant metastases (M). More recently biologic factors have been added to modify TNM stage groups to provide more accurate prognosis for patients. Areas covered: The American Joint Committee on Cancer (AJCC) updated breast cancer staging in 2016 to include T, N, M, tumor grade and expression of estrogen and progesterone receptors and HER2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2019.1582335DOI Listing
February 2019

Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit.

Breast Cancer Res Treat 2019 Feb 13. Epub 2019 Feb 13.

Department of Surgical Oncology, Aix-Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.

Background: Invasive lobular carcinomas (ILCs) represent approximately 10% of all breast cancers. Despite this high frequency, benefit of adjuvant chemotherapy (CT) is still unclear.

Methods: Our objective was to investigate the impact of CT on survival in ILC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05160-9DOI Listing
February 2019

The Vitamins Involved in One-Carbon Metabolisms are Associated with Reduced Risk of Breast Cancer in Overall and Subtypes.

Int J Vitam Nutr Res 2019 Feb 13:1-10. Epub 2019 Feb 13.

1 Department of Nutritional Sciences, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Background: Some micronutrients like folate, vitamin B12, B6, and B2 are the source of coenzymes, which participate in one-carbon metabolism. Any disruption in this metabolism can interfere with DNA replication, repair and regulation of gene expression and ultimately promote the likelihood of carcinogenesis. This study aimed at investigating the relationship between the intakes of micronutrients involved in one-carbon metabolism with breast cancer (BrCa) and its subtype's odds. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1024/0300-9831/a000501DOI Listing
February 2019

Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material.

Breast Cancer Res Treat 2019 Feb 13. Epub 2019 Feb 13.

Department of Health Technology and Services Research, Faculty of Behavioural, Management and Social Sciences, Technical Medical Centre, University of Twente, Enschede, The Netherlands.

Purpose: The estrogen (ER), progesterone (PR), and HER2 status are essential in guiding treatment decisions in breast cancer patients. In daily life, the ER/PR/HER2 status is expected to be commonly tested twice, i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05141-yDOI Listing
February 2019

Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive breast cancer treated with trastuzumab emtansine.

Sci Rep 2019 Feb 12;9(1):1811. Epub 2019 Feb 12.

Department of Surgery, Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Mukogawa-cho 1-1, Nishinomiya, Hyogo, 663-8501, Japan.

The efficacy of trastuzumab emtansine (T-DM1) is prolonged for some patients; however, the predictive factors remain unknown. We focused on a peripheral blood biomarker, the neutrophil-to-lymphocyte ratio (NLR), regarding T-DM1 treatment efficacy. Fifty-three advanced or metastatic breast cancers treated with T-DM1 were retrospectively recruited from three institutes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-37633-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372578PMC
February 2019

The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.

Ann Oncol 2019 Feb 7. Epub 2019 Feb 7.

Departments of Medical Oncology and Dana-Farber Cancer Institute, Boston, MA, USA.

Background: Previous data suggest that the immune microenvironment plays a critical role in HER2-positive breast cancer, however there is little known about the immune profiles of small HER2-positive tumors. In this study we aimed to characterize the immune microenvironment of small HER2-positive breast cancers included in the APT trial, and to correlate the immune markers with pathological and molecular tumor characteristics.

Patients And Methods: The APT trial was a multicenter, single-arm phase II study of paclitaxel and trastuzumab in patients with node-negative HER2-positive breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz047DOI Listing
February 2019
1 Read

Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up.

Breast Cancer Res Treat 2019 Feb 12. Epub 2019 Feb 12.

Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

Background: It remains unclear whether breast cancer subtypes are associated with clinical outcome in patients without any treatment including systemic and radiation therapy as an independent entity. Understanding the survival profiles among subtypes by treatment status could impact optimal selection of treatments.

Methods: Patients were diagnosed with invasive breast cancer from the community hospitals across four geographical regions of the United States. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05142-xDOI Listing
February 2019
1 Read

Locally advanced breast cancer: Tumor-infiltrating lymphocytes as a predictive factor of response to neoadjuvant chemotherapy.

Eur J Surg Oncol 2019 Feb 4. Epub 2019 Feb 4.

Pathology Department at Luis Razetti Oncology Institute, Caracas, Venezuela.

Objective: To evaluate the pathologic response after neoadjuvant chemotherapy in patients with breast cancer according to the stromal tumor-infiltrating lymphocytes (TILs) as well as the evaluation of overall and disease-free survival according to TILs.

Methods: A six years (2008-2013) review was done including patients with locally advanced breast cancer that received neoadjuvant therapy and then surgery. An evaluation of the percentage of TILs was done in the pretreatment biopsies and a correlation analysis and survival curves were done. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejso.2019.01.222DOI Listing
February 2019
1 Read

Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer.

Clin Breast Cancer 2019 Jan 3. Epub 2019 Jan 3.

Department of Medicine and Carbone Cancer Center, University of Wisconsin, Madison, WI. Electronic address:

Background: Increased signaling through growth factor receptor pathways, including HER2, plays a role in resistance to endocrine therapy (ET) in patients with hormone receptor (HR)-positive metastatic breast cancer (MBC). Inhibition of mechanistic target of rapamycin improves outcomes when used in addition to ET in patients with HR-positive MBC, who previously received ET. We hypothesized that the additional use of trastuzumab (T) or everolimus (E) could restore sensitivity to ET in patients with endocrine-resistant, HR-positive, HER2-negative MBC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.12.017DOI Listing
January 2019
1 Read

Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype.

Eur J Surg Oncol 2019 Jan 31. Epub 2019 Jan 31.

Breast Surgery Unit, San Raffaele Hospital, Milan, Italy. Electronic address:

Background: The management of axilla after Primary Systemic Therapy (PST) for breast cancer is a highly debated field. Despite the proven axillary downstaging occurring after PST, there is still some degree of reluctance in applying sentinel node biopsy (SNB) in the neoadjuvant setting.

Patients And Methods: We performed a retrospective analysis on 181 PST patients with axillary positive nodes at presentation treated between 2005 and 2017 at San Raffaele Hospital in Milan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejso.2019.01.219DOI Listing
January 2019
2 Reads

Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France.

BMC Cancer 2019 Feb 11;19(1):140. Epub 2019 Feb 11.

HEVA HEOR, Lyon, France.

Background: Evidence from clinical trials suggests that the addition of bevacizumab to chemotherapy in the first-line treatment of patients with HER2-negative metastatic breast cancer improves progression-free survival (PFS) but not overall survival (OS). However, a retrospective analysis of real-world data from the French Comprehensive Cancer Centers (FCCC) through the Epidemiological Strategy and Medical Economics (ESME) Research Program, suggested that in this setting, the addition of bevacizumab may confer a significant benefit in terms of both PFS and OS. A cost-effectiveness analysis was performed to determine the cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel alone in the first-line treatment of HER2-negative metastatic breast cancer at specialist oncology centers in France. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5335-8DOI Listing
February 2019
1 Read

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells.

Cancers (Basel) 2019 Feb 8;11(2). Epub 2019 Feb 8.

Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, 9 Dublin, Ireland.

Prolonged treatment of HER2 positive breast cancer cells with tyrosine kinase inhibitors (TKIs) leads to the emergence of acquired resistance. However, the effects of continuous TKI exposure on cell fate, and the steps leading to the acquisition of a resistant phenotype are poorly understood. To explore this, we exposed five HER2 positive cells lines to HER2 targeted therapies for periods of up to 4 weeks and examined senescence associated β-galactosidase (SA-β-gal) activity together with additional markers of senescence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11020197DOI Listing
February 2019
1 Read

Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Pharmacoecon Open 2019 Feb 11. Epub 2019 Feb 11.

The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, CH63 4JY, UK.

Eribulin is a recommended treatment option for locally advanced or metastatic breast cancer (LABC/MBC) in adults whose disease has progressed after at least two chemotherapy regimens. The National Institute for Health and Care Excellence (NICE) invited the manufacturer of eribulin (Halaven; Eisai Ltd) to submit evidence for the clinical and cost effectiveness of eribulin for treating LABC/MBC after one chemotherapy regimen in accordance with the institute's Single Technology Appraisal (STA) process. This article presents a summary of the company's evidence, Evidence Review Group (ERG) review and resulting NICE guidance (TA515), issued 28 March 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s41669-018-0114-zDOI Listing
February 2019
1 Read

Evaluating mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer.

Front Pharmacol 2018 25;9:1581. Epub 2019 Jan 25.

Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France.

is a candidate oncogene with a wide variety of deleterious functions in breast cancer. Here, we aimed at investigating in a pilot prospective study the association between mRNA expression levels and the clinical response to neoadjuvant endocrine therapy (ET) in postmenopausal ER-positive (ER+) breast cancer patients. Core surgical biopsy samples before treatment initiation and post-treatment were obtained from 68 patients, and Ki-67 values measured by immunohistochemistry (IHC) were used to identify responders ( = 59) and non-responders ( = 9) after 4 months of ET. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2018.01581DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355665PMC
January 2019
1 Read

Syndecan-1 could be added to hormonal receptors and HER2/neu in routine assessment of invasive breast carcinoma, relation of its expression to prognosis and clinicopathological parameters.

Pathol Res Pract 2019 Feb 2. Epub 2019 Feb 2.

Department of Pathology, Faculty of Medicine, University of Mansoura, Mansoura, 35516, Egypt.

Introduction: Syndecan-1 is heparan sulfate proteoglycans (HSPGs) that is used as coreceptors for signaling of growth factors. The comprehensive effect of syndecan-1 is to augment receptor stimulation at little ligand concentrations. THE GOAL OF THIS RESEARCH: is to study syndecan-1 expression in breast carcinoma and its value in predicting the prognosis in comparison to other clinicopathological parameters. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prp.2019.02.003DOI Listing
February 2019
1 Read

Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.

J Neurosurg 2019 Feb 8:1-9. Epub 2019 Feb 8.

Departments of1Radiation Oncology and.

OBJECTIVEWith increasing survival for patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer in the trastuzumab era, there is an increased risk of brain metastasis. Therefore, there is interest in optimizing intracranial disease control. Lapatinib is a small-molecule dual HER2/epidermal growth factor receptor inhibitor that has demonstrated intracranial activity against HER2+ breast cancer brain metastases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3171/2018.10.JNS182340DOI Listing
February 2019
2 Reads

Radiation Therapy After Breast-Conserving Surgery in Women 70 Years of Age and Older: How Wisely Do We Choose?

Ann Surg Oncol 2019 Feb 8. Epub 2019 Feb 8.

Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Background: Despite data from randomized trials supporting omission of radiation therapy (RT) for women ≥ 70 years of age with T1, estrogen receptor-positive (ER+) tumors undergoing breast-conserving therapy (BCT), RT usage remains high. We reviewed our institutional experience to determine if risk factors for local recurrence or comorbidities influenced use.

Methods: Women ≥ 70 years of age with T1, ER+, human epidermal growth factor receptor 2-negative (HER2-) tumors undergoing BCT in 2010-2012 were identified from a prospectively maintained database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-018-07151-4DOI Listing
February 2019
1 Read

Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population.

Breast Cancer 2019 Feb 8. Epub 2019 Feb 8.

Department of Breast and Medical Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

Background: Trastuzumab emtansine (T-DM1) has been approved since 2013 for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) who had received trastuzumab (Tmab) and taxane. However, no clinical trial has evaluated the efficacy of T-DM1 in those who have previously received pertuzumab (Pmab). This study aimed to compare the efficacy of T-DM1 between patients who had received Tmab and Pmab and those who had received Tmab only in Japanese population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-019-00949-4DOI Listing
February 2019
1 Read

Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study.

Sci Rep 2019 Feb 8;9(1):1710. Epub 2019 Feb 8.

Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

Fulvestrant (Ful) is an effective and widely used agent for first- and second-line treatment of hormone receptor-positive, human epidermal growth factor receptor-2-negative (HR+/HER2-) metastatic breast cancer (MBC). However, there is no evidence of treatment after progression on Ful. Our study aimed to investigate the profile of daily practice regarding therapy after Ful. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-37472-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368624PMC
February 2019
2 Reads
5.078 Impact Factor

Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.

Nat Commun 2019 Feb 8;10(1):657. Epub 2019 Feb 8.

Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, 94305, California, United States.

Genomic changes observed across treatment may result from either clonal evolution or geographically disparate sampling of heterogeneous tumors. Here we use computational modeling based on analysis of fifteen primary breast tumors and find that apparent clonal change between two tumor samples can frequently be explained by pre-treatment heterogeneity, such that at least two regions are necessary to detect treatment-induced clonal shifts. To assess for clonal replacement, we devise a summary statistic based on whole-exome sequencing of a pre-treatment biopsy and multi-region sampling of the post-treatment surgical specimen and apply this measure to five breast tumors treated with neoadjuvant HER2-targeted therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-019-08593-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368565PMC
February 2019
2 Reads

Label-Free Enrichment and Molecular Characterization of Viable Circulating Tumor Cells from Diagnostic Leukapheresis Products.

Clin Chem 2019 Feb 8. Epub 2019 Feb 8.

Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich Heine University Düsseldorf, Düsseldorf, Germany;

Introduction: Circulating tumor cells (CTCs) may be used to improve cancer diagnosis, prognosis, and treatment. However, because knowledge regarding CTC biology is limited and the numbers of CTCs and CTC-positive cancer patients are low, progress in this field is slow. We addressed this limitation by combining diagnostic leukapheresis (DLA) and microfluidic enrichment to obtain large numbers of viable CTCs from metastasized breast cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1373/clinchem.2018.296814DOI Listing
February 2019
1 Read

Transcriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+ breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targets.

BMC Med Genomics 2019 Feb 8;12(1):32. Epub 2019 Feb 8.

Division of Cancer Research and Training, Department of Medicine, Charles R. Drew University of Medicine and Science, 1731 East 120th Street, Los Angeles, CA, 90059, USA.

Background: The Human Epidermal Growth Factor Receptor (EGFR/HER1) can be activated by several ligands including Transforming Growth Factor alpha (TGF-α) and Epidermal Growth Factor (EGF). Following ligand binding, EGFR heterodimerizes with other HER family members, such as HER2 (human epidermal growth factor receptor-2). Previously, we showed that the EGFR is upregulated in trastuzumab resistant HER2 positive (HER2+) breast cancer cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12920-019-0477-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368760PMC
February 2019
1 Read
2.873 Impact Factor

Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.

Breast J 2019 Feb 8. Epub 2019 Feb 8.

Medical Oncology Department, Hospital 12 De Octubre, Madrid, Spain.

Eribulin is active and safe in heavily pre-treated metastatic breast cancer patients. Few safety data have been published in third line. We aimed to report the specific safety profile on third line beyond taxanes and anthracyclines in advanced breast cancer (ABC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/tbj.13199DOI Listing
February 2019
1 Read

Breast cancer subtypes affect the nodal response after neoadjuvant chemotherapy in locally advanced breast cancer: Are we ready to endorse axillary conservation?

Breast J 2019 Feb 7. Epub 2019 Feb 7.

Department of Radiological, Oncological and Pathological Sciences, Sapienza, University of Rome, Rome, Italy.

We evaluated the impact of breast cancer subtypes on pathologic complete response (pCR) in 181 patients with positive nodes undergoing neoadjuvant chemotherapy (NAC). After NAC, patients underwent surgery, with sentinel lymph node biopsy (SLNB) or axillary dissection (ALND). In 28. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/tbj.13206DOI Listing
February 2019
1 Read

Behaviour and characteristics of low-grade ductal carcinoma in situ of the breast: literature review and single centre retrospective series.

Histopathology 2019 Feb 7. Epub 2019 Feb 7.

Division of Pathology, Singapore General Hospital, 20 College Road, Academia, Diagnostics Tower, Singapore, 169856.

Aims: Ductal carcinoma in situ (DCIS) of the breast is a heterogeneous disease that has risen to prominence and more recently controversy, with the advent of screening mammography. Debate about the true biological potential of low nuclear grade DCIS continues to challenge therapeutic considerations. In this study, we carried out a comprehensive literature review of the behaviour, outcomes and current management trials of low-grade DCIS, as well as a retrospective study of a large single institutional series of low-grade DCIS diagnosed at our hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.13837DOI Listing
February 2019
2 Reads

Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings.

J Patient Rep Outcomes 2019 Feb 7;3(1):10. Epub 2019 Feb 7.

Northwestern University Feinberg School of Medicine, 633 N. Saint Clair St., 19th Floor, Chicago, IL, 60611, USA.

Background: Patients with breast cancer experience a variety of disease symptoms and treatment-related side effects that can adversely affect functioning. The breast cancer experience may differ across disease stages and biomarker subtypes. This study identified relevant disease symptoms, treatment-related side effects, and physical functioning impacts in women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s41687-019-0098-1DOI Listing
February 2019

Assessment of Ki-67 as a potential biomarker in patients with breast cancer.

J Genet Eng Biotechnol 2018 Dec 10;16(2):479-484. Epub 2018 Mar 10.

Department of Pathology, National Cancer Institute, Cairo University, Cairo, Egypt.

Breast cancer is the most common cancer in females, it accounts for one third of all malignancies affecting women. Appropriate biomarkers play significant role in predicting the prognosis and decide the specific therapy to each patient. In this study we aimed at evaluating the value of Ki-67 as a prognostic marker in breast cancer patients and to analyze the associations between Ki-67 and their clinicopathological parameters. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S1687157X183002
Publisher Site
http://dx.doi.org/10.1016/j.jgeb.2018.03.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353752PMC
December 2018
2 Reads

Clinical Predictive Factors for the Efficacy of Everolimus in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Multicenter Retrospective Cohort Study in Japan.

Breast Cancer (Auckl) 2019 22;13:1178223418825135. Epub 2019 Jan 22.

Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Purpose: To investigate the clinical predictive factors for the efficacy of everolimus (EVE) for advanced/metastatic breast cancer (AMBC).

Methods: Routine practice data of consecutive patients with AMBC who received EVE at 5 institutions in western Japan were retrospectively analyzed in this cohort study (study registration no.: UMIN 000032569). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1178223418825135DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343452PMC
January 2019
1 Read

A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses.

Sci Rep 2019 Feb 7;9(1):1538. Epub 2019 Feb 7.

Molecular Oncology & Pathology Lab, INGEMM, La Paz University Hospital Health Research Institute-IdiPAZ, Madrid, Spain.

Triple-negative breast cancer is a heterogeneous disease characterized by a lack of hormonal receptors and HER2 overexpression. It is the only breast cancer subgroup that does not benefit from targeted therapies, and its prognosis is poor. Several studies have developed specific molecular classifications for triple-negative breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-38364-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367406PMC
February 2019
1 Read

Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer.

Sci Rep 2019 Feb 7;9(1):1583. Epub 2019 Feb 7.

Department of General Surgical Science, Gunma University Graduate School of Medicine, Gunma, Japan.

Predictive utility of tumor-infiltrating lymphocytes (TILs) in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy (NAC) with concurrent trastuzumab remains unclear. We examined TILs grades of pretreatment cancer tissue specimens and residual tumors after NAC with trastuzumab and determined the predictive utility of the TILs grade in pathological complete response (pCR) and the prognostic power of TILs in HER2-positive breast cancer. This cohort study included 128 HER2-positive breast cancer who received NAC with trastuzumab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-38272-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367461PMC
February 2019
1 Read